The modern approaches to dual antiplatelet therapy in patients at high cardiovascular risk

Atherosclerotic cardiovascular disease is significant part of cardiovascular diseases, the morbidity and mortality from which is constantly increasing all over the world, including and in Ukraine. The methods of treatment specified in the guidelines do not always coincide with everyday medical practice. This is connected, including, with the low adherence of patients to treatment, especially in case of simultaneous administration of several drugs. The type of antiplatelet therapy — dual antiplatelet therapy — is quite important in the secondary prevention of many cardiovascular complications in high-risk patients. Main components of dual antiplatelet therapy — acetylsalicylic acid and clopidogrel have been well studied for several decades when taken simultaneously. The results of many clinical studies of effectiveness are given, as well as the latest clinical recommendations for prescribing a combination of acetylsalicylic acid with clopidogrel in patients with vascular complications. In Ukraine, the drug Clovask — a fixed combination of acetylsalicylic acid and clopidogrel — is presented.

References

1. Roth G.A., Mensah G.A., Johnson C.O. et al. (2020) Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J. Am. Coll. Cardiol., 76: 2982–3021.
2. Banach M., Surma S. (2023) A look to the past — what has had the biggest impact on lipids in the last four decades? A personal perspective. Arch. Med. Sci., 19: 559–564.
3. Vallejo-Vaz A.J., Bray S., Villa G. et al.; DA VINCI Study Investigators (2023) Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI. Cardiovasc. Drugs Ther., 37: 941–953.
4. Vaduganathan M., Mensah G., Turco J.V. et al. (2022) The global burden of cardiovascular diseases and risk: a compass for future health. J. Am. Coll. Cardiol., 80: 2361–2371.
5. Banach M., Surma S., Toth P.P.; endorsed by the International Lipid Expert Panel (ILEP) (2023) 2023: The year in cardiovascular disease — the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch. Med. Sci., 19(6): 1602–1615. doi: 10.5114/aoms/174743.
6. Gomez-Delgado F., Raya-Cruz M., Katsiki N. et al. (2024) Residual cardiovascular risk: When should we treat it? Eur. J. Intern. Med., 120: 17–24. doi: 10.1016/j.ejim.2023.10.013.
7. Woodruff R.C., Tong X., Khan S.S. et al. (2023) Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010–2022. Am. J. Prev. Med., S0749-3797(23)00465-8. doi: 10.1016/j.amepre.2023.11.009.
8. Laranjo L., Lanas F., Sun M.C. et al. (2024) World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update. Glob Heart, 19(1): 8. doi: 10.5334/gh.1278.
9. Mazhar F., Hjemdahl P., Clase C.M. et al. (2022) Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. J. Am. Heart Assoc., 11(14): e025813. doi: 10.1161/JAHA.122.025813.
10. Virk G.S., Sharma A., Khan M.R. et al. (2023) The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Cureus, 15(10): e47032. doi: 10.7759/cureus.47032.
11. Schrör K., Verheugt F.W.A., Trenk D. (2023) Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors). Thromb. Haemost., 123(2): 166–176. doi: 10.1055/s-0042-1758654.
12. Arockiam S., Staniforth B., Kepreotis S. et al. (2023) A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. Int. J. Mol. Sci., 24(13): 11132. doi.org/10.3390/ijms241311132.
13. Amarenco P., Denison H., Evans S.R. et al. (2020) Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 51: 3504–3513.
14. Bonaca M.P., Scirica B.M., Creager M.A. et al. (2013) Vorapaxar in patients with peripheral artery disease: Results from TRA2° P-TIMI 50. Circulation, 127: 1522–1529.
15. Yeh R.W., Secemsky E.A., Kereiakes D.J. et al. (2016) Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year after Percutaneous Coronary Intervention. JAMA, 315: 1735–1749.
16. Costa F., van Klaveren D., James S. et al. (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet, 389: 1025–1034.
17. Chan B.P.L., Wong L.Y.H., Tan B.Y.Q. et al. (2024) Dual Antiplatelet Therapy for the Acute Management and Long-term Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack, An Updated Review. J. Cardiovasc. Developm. Dis., 11(2): 48. doi.org/10.3390/jcdd11020048.
18. Kleindorfer D.O., Towfighi A., Chaturvedi S. et al. (2021) 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline from the American Heart Association/American Stroke Association. Stroke, 52: e364–e467.
19. Campbell C.L., Smyth S., Montalescot G., Steinhubl S.R. (2007) Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA, 297: 2018–2024.
20. Roshandel G., Khoshnia M., Poustchi H. et al. (2019) Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): A pragmatic, cluster-randomised trial. Lancet, 394: 672–683.
21. Visseren F.L.J., Mach F., Smulders Y.M. et al. (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J., 42: 3227–3337.
22. Arnett D.K., Blumenthal R.S., Albert M.A. et al. (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 74: e177–e232.
23. Jourdi G., Lordkipanidzé M., Philippe A. et al. (2021) Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. Int. J. Mol. Sci., 22: 13079.
24. Galli M., Angiolillo D.J. (2024) Role of the P2Y12 receptor on thrombus formation and evolution in therapeutic strategies. Expert Opin. Ther. Targets: 1–4. doi: 10.1080/14728222.2024.2315017.
25. Galli M., Franchi F., Rollini F. et al. (2023) Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc. Med., 33(3): 133–138. doi: 10.1016/j.tcm.2021.12.007.
26. Sibbing D., Aradi D., Alexopoulos D. et al. (2019) Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc. Interv., 12(16): 1521–1537. doi: 10.1016/j.jcin.2019.03.034.
27. Byrne R.A., Rossello X., Coughlan J.J. et al.; ESC Scientific Document Group (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur. Heart J., 44(38): 3720–3826. doi: 10.1093/eurheartj/ehad191. PMID: 37622654.
28. De Filippo O., Piroli F., Bruno F. et al. (2024) De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. BMJ Evid. Based Med.: bmjebm-2023-112476. doi: 10.1136/bmjebm-2023-112476.
29. Morrow D.A., Braunwald E., Bonaca M.P. et al. (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med., 366: 1404–1413.
30. Kang J., Park K.W., Lee H. et al. (2023) Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation, 147(2): 108–117. doi: 10.1161/CIRCULATIONAHA.122.062770.
31. Marquis-Gravel G., Robert-Halabi M., Bainey K.R. et al. (2022) The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. Can. J.Cardiol., 38(10 Suppl. 1): S79–S88. doi: 10.1016/j.cjca.2022.02.022.
32. McLean D.S., Sabatine M.S., Guo W. et al. (2007) Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J .Thromb. Thrombolysis, 24(2): 85–91. doi: 10.1007/s11239-007-0016-x.
33. Mahaffey K.W., Wojdyla D.M., Carroll K. et al.; PLATO Investigators (2011) Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 124(5): 544–554. doi: 10.1161/CIRCULATIONAHA.111.047498.
34. Michelson A.D., Frelinger A.L. 3rd, Braunwald E. et al.; TRITON-TIMI 38 Investigators (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J., 30(14): 1753–1763. doi: 10.1093/eurheartj/ehp159.
35. Bhatt D.L., Fox K.A., Hacke W. et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med., 354: 1706–1717.
36. Wong K.S., Chen C., Fu J. et al. (2010) Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): A randomised, open-label, blinded-endpoint trial. Lancet Neurol., 9: 489–497.
37. Chimowitz M.I., Lynn M.J., Derdeyn C. et al. (2011) SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N. Engl. J. Med., 365: 993–1003.
38. Gao Y., Chen W., Pan Y. et al. (2023) Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke. N. Engl. J. Med., 389: 2413–2424.
39. Kleindorfer D.O., Towfighi A., Chaturvedi S. et al. (2021) 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline from the American Heart Association/American Stroke Association. Stroke, 52: e364–e467.
40. Franczyk B., Gluba-Brzózka A., Jurkiewicz Ł. et al. (2018) Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Expert. Opin. Pharmacother., 19(17): 1857–1865. doi: 10.1080/14656566.2018.1532501.